|
 (Bloomberg) -- Ford Motor Co., riding a wave of momentum from new models and new management, handily beat expectations with third-quarter earnings that outran the economic effects of the coronavirus pandemic.Fueled by strong sales of pricey pickups, Ford posted adjusted earnings per share of 65 cents, well above the 19 cents analyst consensus forecast. Big profits in North America offset weakness overseas, allowing the company to revise its full-year forecast. It now expects to stay in the black this year, a reversal from an earlier outlook for its first annual loss in a decade.Ford's stock rose as much as 7.8% in postmarket trading after closing Wednesday at $7.70. The shares are down about 17% this year.The long-suffering automaker is enjoying a surge in sentiment since industry veteran Jim Farley became chief executive officer Oct. 1, replacing retiring Jim Hackett, to whom Wall Street never warmed. Intense and demanding, Farley is expected to jumpstart a turnaround that has been sputtering for years. The latest quarterly results help position the company to put the worst behind it.Ford said adjusted earnings before interest and taxes came to $3.6 billion in the quarter compared with $1.8 billion a year ago. Revenue in the quarter was $37.5 billion, above the $33.98 billion analysts anticipated.Unresolved IssuesFarley said the bullish performance belies underlying woes that need to be resolved before the carmaker can achieve its goal of sustainable profit margins above 10% in its core North American market."
|
|
Remdesivir generated $873 million in sales during the third quarter, mostly in the U.S., the company said.
|
RELATED ARTICLES | | |
|
 In the first quarter of sales of its COVID-19 antiviral drug, Gilead Sciences Inc. produced better profit and sales than expected, buts its beleaguered shares were hit by a reduction in its annual sales forecast Wednesday.
|
|
 NCR Corp.'s 3Q revenues fell 11% to $1.59 billion year-over-year dragged down by a 26% decline in hardware sales. However, revenues of the ATM (automated teller machine) and POS (Point-Of-Sale) hardware and software solution provider came ahead of analysts' estimates of $1.55 billion.NCR's (NCR) ATM hardware sales plunged 40% as the COVID-19 pandemic impacted ATM installation activities. Moreover, its SCO/POS (Self-Checkout/Point-Of-Sale) hardware sales shrank 6% on a year-on-year basis.The company's 3Q adjusted EPS decreased by 26% to $0.54 year-on-year but came ahead of the Street estimates of $0.36.NCR's CEO Michael Hayford said, "Our third quarter performance reflects solid execution of our strategy and the resiliency of our solutions in a difficult operating environment that continues to be impacted by COVID-19." He further noted, "Looking ahead, we still face a challenging operating environment but we remain confident in our ability to execute our strategy and grow recurring revenue, drive cash flow generation and expand margins." (See NCR stock analysis on TipRanks).Ahead of its earnings release, J.P. Morgan analyst Paul J Chung upgraded the stock to Buy from Hold and raised the price target to $27 (23% upside potential) from $21. Chung is encouraged by NCR's margin structure and free cash flow outlook. The analyst sees modest growth in ATMs per branch and forecasts a steady fundamental recovery over the next 6-12 months.Currently, the Street is bullish on the stock. The Strong Buy analyst consensus is based on
|
|
Gilead Sciences' revenue rose 17%, helped by sales of its antiviral drug Remdesivir that has become a standard treatment for hospitalized Covid-19 patients.
|
RELATED ARTICLES | | |
|
Results from industrial giants Caterpillar and 3M show demand from commercial customers is on shaky ground as the Covid-19 pandemic continues to disrupt work routines and commerce.
|
|
Private Label